Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eliglustat - Sanofi

Next Previous
Drug Profile

Eliglustat - Sanofi

Alternative Names: Cerdelga; Eliglustat; Eliglustat tartrate; Genz-112638; GZ 385660

Latest Information Update: 07 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer Sanofi
  • Class 2 ring heterocyclic compounds; Amides; Pyrrolidines; Small molecules
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease type I
  • Phase III Gaucher's disease type III

Most Recent Events

  • 06 Feb 2025 Sanofi announces intention to submit regulatory application for Gaucher's disease type I (In children) in the European Union in fourth quarter of 2024
  • 06 Dec 2024 Registered for Gaucher's disease type I (In children, In adolescents, Treatment-experienced, In adults) in European Union (PO)
  • 17 Oct 2024 Preregistration for Gaucher's disease type I (Treatment-experienced, In adolescents, In children, In adults) in European Union (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top